Last reviewed · How we verify
Formatris 24µg — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Formatris 24µg (Formatris 24µg) — MEDA Pharma GmbH & Co. KG.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Formatris 24µg TARGET | Formatris 24µg | MEDA Pharma GmbH & Co. KG | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Formatris 24µg CI watch — RSS
- Formatris 24µg CI watch — Atom
- Formatris 24µg CI watch — JSON
- Formatris 24µg alone — RSS
Cite this brief
Drug Landscape (2026). Formatris 24µg — Competitive Intelligence Brief. https://druglandscape.com/ci/formatris-24-g. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab